메뉴 건너뛰기




Volumn 119, Issue 1-3, 2010, Pages 153-159

Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities

Author keywords

Depot; Fluphenazine; Haloperidol; Risperidone; Schizophrenia

Indexed keywords

FLUPHENAZINE; HALOPERIDOL; RISPERIDONE;

EID: 77952672789     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.02.1066     Document Type: Article
Times cited : (16)

References (32)
  • 1
    • 57649202651 scopus 로고    scopus 로고
    • Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic
    • Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int. J. Clin. Pract. 2009, 63(1):140-150.
    • (2009) Int. J. Clin. Pract. , vol.63 , Issue.1 , pp. 140-150
    • Citrome, L.1
  • 2
    • 67749095284 scopus 로고    scopus 로고
    • Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic
    • Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int. J. Clin. Pract. 2009, 63(8):1237-1248.
    • (2009) Int. J. Clin. Pract. , vol.63 , Issue.8 , pp. 1237-1248
    • Citrome, L.1
  • 3
    • 72449129531 scopus 로고    scopus 로고
    • Paliperidone palmitate-review of the efficacy, safety, and cost of a new second-generation depot antipsychotic medication
    • Citrome L. Paliperidone palmitate-review of the efficacy, safety, and cost of a new second-generation depot antipsychotic medication. Int. J. Clin. Pract. 2010, 64(2):216-239.
    • (2010) Int. J. Clin. Pract. , vol.64 , Issue.2 , pp. 216-239
    • Citrome, L.1
  • 4
    • 0029910610 scopus 로고    scopus 로고
    • Utilization of depot neuroleptic medication in psychiatric inpatients
    • Citrome L., Levine J., Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol. Bull. 1996, 32(3):321-326.
    • (1996) Psychopharmacol. Bull. , vol.32 , Issue.3 , pp. 321-326
    • Citrome, L.1    Levine, J.2    Allingham, B.3
  • 5
    • 0031705379 scopus 로고    scopus 로고
    • Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health
    • Citrome L., Levine J., Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr. Q. 1998, 69(4):283-300.
    • (1998) Psychiatr. Q. , vol.69 , Issue.4 , pp. 283-300
    • Citrome, L.1    Levine, J.2    Allingham, B.3
  • 6
    • 0034100648 scopus 로고    scopus 로고
    • Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
    • Citrome L., Levine J., Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 2000, 51(5):634-638.
    • (2000) Psychiatr. Serv. , vol.51 , Issue.5 , pp. 634-638
    • Citrome, L.1    Levine, J.2    Allingham, B.3
  • 7
    • 0036787358 scopus 로고    scopus 로고
    • Use of mood stabilizers among patients with schizophrenia, 1994-2001
    • Citrome L., Jaffe A., Levine J., Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr. Serv. 2002, 53(10):1212.
    • (2002) Psychiatr. Serv. , vol.53 , Issue.10 , pp. 1212
    • Citrome, L.1    Jaffe, A.2    Levine, J.3    Allingham, B.4
  • 8
    • 4444286682 scopus 로고    scopus 로고
    • Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients
    • Citrome L., Jaffe A., Levine J., Allingham B., Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr. Serv. 2004, 55(9):1006-1013.
    • (2004) Psychiatr. Serv. , vol.55 , Issue.9 , pp. 1006-1013
    • Citrome, L.1    Jaffe, A.2    Levine, J.3    Allingham, B.4    Robinson, J.5
  • 9
    • 23044440036 scopus 로고    scopus 로고
    • Dosing of second-generation antipsychotic medication in a state hospital system
    • Citrome L., Jaffe A., Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J. Clin. Psychopharmacol. 2005, 25(4):388-391.
    • (2005) J. Clin. Psychopharmacol. , vol.25 , Issue.4 , pp. 388-391
    • Citrome, L.1    Jaffe, A.2    Levine, J.3
  • 10
    • 30344469722 scopus 로고    scopus 로고
    • Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies
    • Citrome L., Jaffe A., Levine J., Lindenmayer J.P. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J. Clin. Psychiatry 2005, 66(12):1512-1516.
    • (2005) J. Clin. Psychiatry , vol.66 , Issue.12 , pp. 1512-1516
    • Citrome, L.1    Jaffe, A.2    Levine, J.3    Lindenmayer, J.P.4
  • 11
    • 33747024519 scopus 로고    scopus 로고
    • Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004
    • Citrome L., Jaffe A., Levine J., Martello D. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr. Serv. 2006, 57(8):1132-1139.
    • (2006) Psychiatr. Serv. , vol.57 , Issue.8 , pp. 1132-1139
    • Citrome, L.1    Jaffe, A.2    Levine, J.3    Martello, D.4
  • 12
    • 33847045551 scopus 로고    scopus 로고
    • Datapoints: the ups and downs of dosing second-generation antipsychotics
    • Citrome L., Jaffe A., Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr. Serv. 2007, 58(1):11.
    • (2007) Psychiatr. Serv. , vol.58 , Issue.1 , pp. 11
    • Citrome, L.1    Jaffe, A.2    Levine, J.3
  • 13
    • 68049131363 scopus 로고    scopus 로고
    • How dosing of ziprasidone in a state hospital system differs from product labeling
    • Citrome L., Jaffe A., Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J. Clin. Psychiatry 2009, 70(7):975-982.
    • (2009) J. Clin. Psychiatry , vol.70 , Issue.7 , pp. 975-982
    • Citrome, L.1    Jaffe, A.2    Levine, J.3
  • 14
    • 74849092225 scopus 로고    scopus 로고
    • Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009
    • Citrome L., Jaffe A., Levine J. Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009. Psychiatr. Serv. 2010, 61(1):9.
    • (2010) Psychiatr. Serv. , vol.61 , Issue.1 , pp. 9
    • Citrome, L.1    Jaffe, A.2    Levine, J.3
  • 15
    • 12844251255 scopus 로고    scopus 로고
    • Long-acting injectable risperidone
    • Ehret M.J., Fuller M.A. Long-acting injectable risperidone. Ann. Pharmacother. 2004, 38(12):2122-2127.
    • (2004) Ann. Pharmacother. , vol.38 , Issue.12 , pp. 2122-2127
    • Ehret, M.J.1    Fuller, M.A.2
  • 16
    • 1442348069 scopus 로고    scopus 로고
    • Long-acting risperidone: a review of its use in schizophrenia
    • Harrison T.S., Goa K.L. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004, 18(2):113-132.
    • (2004) CNS Drugs , vol.18 , Issue.2 , pp. 113-132
    • Harrison, T.S.1    Goa, K.L.2
  • 17
    • 0037278766 scopus 로고    scopus 로고
    • Antipsychotic medication coprescribing in a large state hospital system
    • Jaffe A.B., Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 2003, 12(1):41-48.
    • (2003) Pharmacoepidemiol. Drug Saf. , vol.12 , Issue.1 , pp. 41-48
    • Jaffe, A.B.1    Levine, J.2
  • 18
    • 0346120179 scopus 로고    scopus 로고
    • Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia
    • Jaffe A.B., Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J. Clin. Psychiatry 2003, 64(Suppl 17):3-6.
    • (2003) J. Clin. Psychiatry , vol.64 , Issue.SUPPL. 17 , pp. 3-6
    • Jaffe, A.B.1    Levine, J.2
  • 19
    • 0036076837 scopus 로고    scopus 로고
    • A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients
    • Javitt D.C., Cienfuegos A., Miniati M., et al. A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients. J. Clin. Psychiatry 2002, 63(7):585-590.
    • (2002) J. Clin. Psychiatry , vol.63 , Issue.7 , pp. 585-590
    • Javitt, D.C.1    Cienfuegos, A.2    Miniati, M.3
  • 20
    • 77952671728 scopus 로고    scopus 로고
    • Johnson and Johnson. FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia. Press release, 31 July 2009. Available at: Accessed 2 September 2009.
    • Johnson and Johnson, 2009. FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia. Press release, 31 July 2009. Available at: Accessed 2 September 2009. http://www.jnj.com/connect/news/all/20090731_153000.
    • (2009)
  • 21
    • 4444296161 scopus 로고    scopus 로고
    • Antipsychotic Medication Utilization in a State Mental Hospital System, 1994-2000, Chap. 15
    • Substance Abuse and Mental Health Services Administration, Rockville, MD, R.W. Manderscheid, M.J. Henderson (Eds.) Mental Health United States 2002
    • Levine J., Jaffe A.B. Antipsychotic Medication Utilization in a State Mental Hospital System, 1994-2000, Chap. 15. DHHS Pub Number (SMA) 3938 2004, 199-208. Substance Abuse and Mental Health Services Administration, Rockville, MD. R.W. Manderscheid, M.J. Henderson (Eds.).
    • (2004) DHHS Pub Number (SMA) 3938 , pp. 199-208
    • Levine, J.1    Jaffe, A.B.2
  • 22
    • 0018775268 scopus 로고
    • The role of depot neuroleptics in the treatment of schizophrenic patients
    • Levine J., Schooler N.R., Cassano G.B. The role of depot neuroleptics in the treatment of schizophrenic patients. Psychol. Med. 1979, 9(2):383-386.
    • (1979) Psychol. Med. , vol.9 , Issue.2 , pp. 383-386
    • Levine, J.1    Schooler, N.R.2    Cassano, G.B.3
  • 23
    • 71449109074 scopus 로고    scopus 로고
    • Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia
    • Mohamed S., Rosenheck R., Harpaz-Rotem I., Leslie D., Sernyak M.J. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr. Q. 2009, 80(4):241-249.
    • (2009) Psychiatr. Q. , vol.80 , Issue.4 , pp. 241-249
    • Mohamed, S.1    Rosenheck, R.2    Harpaz-Rotem, I.3    Leslie, D.4    Sernyak, M.J.5
  • 24
    • 34250005736 scopus 로고    scopus 로고
    • Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care
    • Niaz O.S., Haddad P.M. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr. Scand. 2007, 116(1):36-46.
    • (2007) Acta Psychiatr. Scand. , vol.116 , Issue.1 , pp. 36-46
    • Niaz, O.S.1    Haddad, P.M.2
  • 25
    • 77952668428 scopus 로고    scopus 로고
    • Otsuka Pharmaceutical Development & Commercialization, Inc., 2008. Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients with Schizophrenia (ASPIRE). Registry entry, 7 Aug 2008. Available at: Accessed 31 Oct.
    • Otsuka Pharmaceutical Development & Commercialization, Inc., 2008. Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients with Schizophrenia (ASPIRE). Registry entry, 7 Aug 2008. Available at: Accessed 31 Oct 2008. http://clinicaltrials.gov/ct2/show/NCT00731549.
    • (2008)
  • 26
    • 76949089882 scopus 로고    scopus 로고
    • Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries
    • Peuskens J., Olivares J.M., Pecenak J., et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr. Med. Res. Opin. 2010, 26(3):501-509.
    • (2010) Curr. Med. Res. Opin. , vol.26 , Issue.3 , pp. 501-509
    • Peuskens, J.1    Olivares, J.M.2    Pecenak, J.3
  • 27
    • 77952673745 scopus 로고    scopus 로고
    • Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up
    • Mar 12 [Electronic publication]
    • Taylor D., Cornelius V. Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up. J. Psychopharmacol. 2009, Mar 12 [Electronic publication].
    • (2009) J. Psychopharmacol.
    • Taylor, D.1    Cornelius, V.2
  • 28
    • 33846284148 scopus 로고    scopus 로고
    • Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome
    • Taylor D.M., Young C., Patel M.X. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int. J. Neuropsychopharmacol. 2006, 9(6):685-694.
    • (2006) Int. J. Neuropsychopharmacol. , vol.9 , Issue.6 , pp. 685-694
    • Taylor, D.M.1    Young, C.2    Patel, M.X.3
  • 30
    • 62649096283 scopus 로고    scopus 로고
    • Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice
    • Taylor D., Fischetti C., Sparshatt A., Thomas A., Bishara D., Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J. Clin. Psychiatry 2009, 70(2):196-200.
    • (2009) J. Clin. Psychiatry , vol.70 , Issue.2 , pp. 196-200
    • Taylor, D.1    Fischetti, C.2    Sparshatt, A.3    Thomas, A.4    Bishara, D.5    Cornelius, V.6
  • 31
    • 0029128286 scopus 로고
    • Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen
    • Weiden P., Rapkin B., Zygmunt A., et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr. Serv. 1995, 46(10):1049-1054.
    • (1995) Psychiatr. Serv. , vol.46 , Issue.10 , pp. 1049-1054
    • Weiden, P.1    Rapkin, B.2    Zygmunt, A.3
  • 32
    • 33745092184 scopus 로고    scopus 로고
    • Health resource utilization associated with switching to risperidone long-acting injection
    • Young C.L., Taylor D.M. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr. Scand. 2006, 114(1):14-20.
    • (2006) Acta Psychiatr. Scand. , vol.114 , Issue.1 , pp. 14-20
    • Young, C.L.1    Taylor, D.M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.